Detection and quantification of residual disease in chronic myelogenous leukemia

Leukemia

Volumn 14, Issue 6, 2000, Pages 998-1005

  Hochhaus, A ^a   Weisser, A ^a   La Rosee P ^a   Emig, M ^a   Muller M C ^a   Saussele S ^a   Reiter, A ^a   Kuhn, C ^a   Berger, U ^a   Hehlmann, R ^a   Cross, N C P ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

BCR ABL; CML; Minimal residual disease; Quantitative PCR

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA;

ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD SAMPLING; CANCER RECURRENCE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; HUMAN; MINIMAL RESIDUAL DISEASE; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 0034051281     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401811     Document Type: Review

References (90)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1501.
2. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukaemia detected by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Sawyers CL. Chronic myeloid leukemia. New Engl J Med 1999; 340: 1330-1340.
4. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93-99.
5. Stam K, Heisterkamp N, Grosveld G, de Klein A, Verma RS, Coleman M, Dosik H, Groffen J. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. New Engl J Med 1985; 313: 1429-1433.
6. Melo JV, Gordon DE, Cross NCP, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81: 158-165.
7. Thijsen SFT, Schuurhuis GJ, van Oostveen JW, Ossenkoppele GJ. Chronic myeloid leukemia from basics to bedside. Leukemia 1999; 13: 1646-1674.
8. Hehlmann R, Heimpel H. Current aspects of drug therapy in Philadelphia-positive CML: Correlation of tumor burden with survival. Leuk Lymphoma 1996; 22 (Suppl. 1): 161-167.
9. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94-97.
10. Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H. Suppression on cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 1998; 16: 3279-3285.
11. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
12. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML, Suryanarayan K, Homge M, Redner A, Gray J, Pinkel D. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization. Science 1990; 250: 559-562.
13. Nacheva E, Holloway T, Brown K, Bloxham D, Green AR. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol 1994; 87: 409-412.
14. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NCP. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Blood 1996; 88: 2236-2240.
15. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
16. Weber-Matthiesen K, Winkemann M, Müller-Hermelink A, Schlegelberger B, Grote W. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to characterization of tumor cells. J Histochem Cytochem 1992; 40: 171-175.
17. Haferlach T, Winkemann M, Nickenig C, Meeder M, Ramm-Petersen L, Schoch R, Nickelsen M, Weber-Matthiesen K, Schlegelberger B, Schoch C, Gassmann W, Löffler H. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 1997; 97: 99-106.
18. Bentz M, Cabot G, Moos M, Speicher MR, Ganser A, Lichter P, Döhner H. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994; 83: 1922-1928.
19. Garcia-Isidoro M, Tabernero MD, Garcia JL, Najera ML, Hernandez JM, Wiegant J, Raap A, San Miguel J, Orfao A. Detection of the Mbcr/abl translocation in chronic myeloid leukemia by fluorescence in situ hybridization: comparison with conventional cytogenetics and implications for minimal residual disease detection. Hum Pathol 1997; 28: 154-159.
20. Cuneo A, Bigoni R, Emmanuel B, Smit E, Rigolin GM, Roberti MG, Bardi MG, Piva N, Scapoli G, Castoldi G, Van den Berghe H, Hagemeijer A. Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Leukemia 1998; 12: 1718-1723.
21. Yanagi M, Shinjo K, Takeshita A, Tobita T, Yano K, Kobayashi M, Terasaki H, Naoe T, Ohnishi K, Ohno R. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia 1999; 13: 542-552.
22. Chase A, Grand F, Zhang JG, Blackett N, Goldman J, Gordon M. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in-situ hybridization. Genes Chromosom Cancer 1997; 18: 246-253.
23. Cox Froncillo MC, Cantonetti M, Masi M, Lentini R, Giudiceandrea P, Maffei L, Tribalto M, Amadori S, Papa G. Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. Cancer Genet Cytogenet 1995; 84: 15-18.
24. Mühlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G, Duba HC. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission asssessment. Genes Chromosom Cancer 1998; 21: 90-100.
25. Cox Froncillo MC, Maffei L, Cantonetti M, Del Poeta G, Lentini R, Bruno A, Masi M, Tribalto M, Amadori S. FISH analysis for CML monitoring? Ann Hematol 1996; 73: 113-119.
26. Tchirkov A, Giollant M, Tavernier F, Briancon G, Tournilhac O, Kwiatkowski F, Philippe P, Choufi B, Demeocq F, Travade P, Malet P. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-α therapy. Br J Haematol 1998; 101: 552-557.
27. Verfaillie C, Bhatia R, Miller W, Mortari F, Roy V, Burger S, McCullough J, Stieglbauer K, Dewald G, Heimfeld S, Miller JS, McGlave P. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87: 4770-4779.
28. Kirk JA, Reems JA, Roecklein BA, Van Devanter DR, Bryant EM, Radich J, Edmands S, Lee A, Torok Storb B. Benign marrow progenitors are enriched in the CD34+/HLA-DRlo population but not in the CD34+/CD38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. Blood 1995; 86: 737-743.
29. Sinclair PB, Green AR, Grace C, Nacheva EP. Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. Blood 1997; 90: 1395-1402.
30. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 1996; 92: 2315-2321.
31. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM, Spurbeck JL, Silver RT. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91: 3357-3365.
32. Grand F, Kulkarni S, Chase A, Goldman JM, Gordon MY, Cross NCP. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, during progression of chronic myeloid leukemia. Cancer Res 1999; 59: 3870-3674.
33. El Rifai W, Ruutu T, Vettentanta K, Temtamy S, Knuutila S. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase-FISH study. Br J Haematol 1996; 92: 365-369.
34. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995; 86: 2343-2349.
35. Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin R. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogonous leukemia. Bone Marrow Transplant 1997; 19: 565-570.
36. Reiter A, Skladny H, Hochhaus A, Seifarth W, Heimpel H, Bartram CR, Cross NCP, Hehlmann R. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 1997; 97: 86-93.
37. Fishleder AJ, Shadrach B, Tuttle C. bcr rearrangement: potential false positive secondary to an EcoRI restriction fragment length polymorphism. Leukemia 1989; 3: 746-748.
38. Grossman A, Mathew A, O'Connell MP, Tiso P, Distenfeld A, Benn P. Multiple restriction enzyme digests are required to rule out polymorphism in the molecular diagnosis of chronic myeloid leukemia. Leukemia 1990; 4: 63-64.
39. Popenoe DW, Schaefer Rego K, Mears JG, Bank A, Leibowitz D. Frequent and extensive deletion during the 9,22 translocation in CML. Blood 1986; 68: 1123-1128.
40. Bartram CR, Bross Bach U, Schmidt H, Waller HD. Philadelphia-positive chronic myelogenous leukemia with breakpoint 5′ of the breakpoint cluster region but within the bcr gene. Blut 1987; 55: 505-511.
41. Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, Rege Cambrin G, Mazza U, Gavosto F. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990; 76: 1819-1824.
42. Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, LeBeau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 1997; 15: 26-36.
43. Verschraegen CF, Talpaz M, Hirsch Ginsberg CF, Pherwani R, Rios MB, Stass SA, Kantarjian HM. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 1995; 85: 2705-2710.
44. Steegmann JL, Requena MJ, Casaclo LF, Pico M, Panarrubia MJ, Ferro MT, Resino M, Fernandez-Ranada JM. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-ALPHA). Am J Hematol 1996; 53: 169-174.
45. Yoffe G, Blick M, Kantarjian H, Spitzer G, Gutterman J, Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. Blood 1987; 69: 961-963.
46. Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994; 83: 3629-3637.
47. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 1996; 106: 442-448.
48. Morgan GJ, Hughes T, Janssen JW, Gow J, Guo AP, Goldman JM, Wiedemann LM, Bartram CR. Polymerase chain reaction for detection of residual leukaemia. Lancet 1989; 1: 928-929.
49. Hughes T, Martiat P, Morgan G, Sawyers C, Witte ON, Goldman JM. Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet 1990; 335: 50.
50. Hughes T, Janssen JWG, Morgan G, Martiat P, Saglio G, Pignon JM, Pignatti FP, Mills K, Keating A, Gluckman E, Bartram CR, Goldman JM. False-positive results with PCR to detect leukaemia-specific transcript. Lancet 1990; 335: 1037-1038.
51. Hughes T, Goldman JM. Improved results with PCR for chronic myeloid leukaemia. Lancet 1990; 336: 812.
52. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
53. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
54. Malinge MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Guilhot F, Tanzer J, Grandchamp B. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy. Br J Haematol 1992; 82: 701-707.
55. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
56. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
57. Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208-211.
58. Rubinstein R, Purves LR. A novel BCR-ABL rearrangement in a Philadelphia chromosome-positive chronic myelogenous leukaemia variant with thrombocythaemia. Leukemia 1998; 12: 230-232.
59. Clarkson B, Strife A. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 1993; 7: 1683-1721.
60. Morley A. Quantifying leukemia. New Engl J Med 1998; 339: 627-629.
61. van Dongen JJM, Maclntyre EA, Gabert JA, Delabesse E., Rossi V, Saglio G, Gotardi E, Rambaldi A, Dotti G, Giesinger F, Parreira A, Gameiro P, Gonzalez Diaz M, Malec M, Langerak AW, San Miguel JF, Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999; 12: 1901-1928.
62. Cross NCP. Assessing residual leukaemia. Baillières Clin Haematol 1997; 10: 389-403.
63. Cross NCP, Feng L, Zhang JG, Goldman JM. Competitive PCR to monitor residual disease after bone marrow transplantation for chronic myeloid leukaemia. In: Borden EC, Goldman JM, Grignani F (eds). Molecular Diagnosis and Monitoring of Leukaemia and Lymphoma. Ares-Serono Symposia Publications: Rome, 1994, pp 119-126.
64. Potter MN, Cross NCP, van Dongen JJ, Saglio G, Oakhill A, Bartram CR, Goldman JM. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia 1993; 7: 1302-1314.
65. Reiter E, Greinix HT, Keil F, Brugger S, Rabitsch W, Schulenburg A, Mannhalter C, Schwarzinger I, Worel N, Volc-Platzer B, Fischer G, Dieckmann K, Hinterberger W, Schneider B, Haas OA, Geissler K, Kalhs P. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999; 78: 507-513.
66. Zhang JG, Lin F, Chase A, Goldman JM, Cross NCP. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996; 87: 2588-2593.
67. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-α. Br J Haematol 1995; 91: 126-131.
68. Biernaux C, Loos M, Sels A, Huez C, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 88: 3118-3122.
69. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biological significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367.
70. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996; 10: 751-756.
71. Lion T, Izraeli S, Henn T, Gaiger A, Mor W, Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992; 6: 495-499.
72. Thompson JD, Brodsky I, Yunis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992; 79: 1629-1635.
73. Nagel S, Schmidt M, Thiede C, Huhn D, Neubauer A. Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res 1996; 24: 4102-4103.
74. Delage R, Soiffer RJ, Dear K, Ritz J. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood 1991; 78: 2759-2767.
75. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478.
76. Lin F, Kirkland MA, van Rhee F, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NCP. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1996; 18: 1147-1152.
77. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3303.
78. Raanani P, Dazzi F, Sohal J, Szydlo R, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997; 99: 945-950.
79. Corsetti MT, Lerma E, Dejana A, Basta P, Ferrara R, Benvenuto F, Vassallo F, Abate M, Piaggio G, Parodi C, Sessarego M, Pira GL, Manca F, Carella AM. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor ceils for autografting in chronic myelogenous leukemia. Leukemia 1999; 13: 999-1008.
80. Hochhaus A, Reiter A, Saußele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PCA, Allan N. Hehlmann R, Goldman JM, Cross NCP, for the German CML Study Group and the UK MRC CML Study Group. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myeloid leukaemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000; 95: 62-66.
81. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998; 16: 1526-1531.
82. Reiter A, Marley SB, Hochhaus A, Sohal J, Raanani P, Hehlmann R, Gordon MY, Goldman JM, Cross NCP. BCR-ABL positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-α. Br J Haematol 1998; 102: 1271-1278
83. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Guerts van Kessel A, de Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102: 768-774.
84. Preudhomme C, Révillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999; 13: 957-964.
85. Eder M, Battner K, Kafert S, Stucki A, Ganser A, Hertenstein B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13: 1383-1389.
86. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107: 587-599.
87. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
88. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997; 22: 130-138.
89. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler™: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.
90. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.